Endovastec(SH:688016) Shang Hai Zheng Quan Bao·2026-02-27 21:10Financial Performance Summary - The company achieved total operating revenue of 1.3506 billion yuan, an increase of 11.96% year-on-year [2] - Operating profit was 653.89 million yuan, a decrease of 1.10% year-on-year [2] - Total profit reached 653.37 million yuan, a slight increase of 0.18% year-on-year [2] - Net profit attributable to shareholders of the parent company was 563.21 million yuan, up 12.17% year-on-year [2] - The basic earnings per share increased by 14.25% to 4.65 yuan [2] - Total assets at the end of the reporting period were 4.6405 billion yuan, an increase of 8.13% from the beginning of the year [2] - Shareholders' equity attributable to the parent company was 4.0757 billion yuan, up 7.48% from the beginning of the year [2] - Net asset value per share attributable to the parent company was 33.63 yuan, an increase of 9.03% [2] Business Operations and Factors Influencing Performance - The company focused on innovative products, enhancing its domestic leading position while expanding into lower-tier markets and offering customized treatment solutions [3] - Overseas sales revenue exceeded 250 million yuan, growing over 55% year-on-year, contributing to more than 18% of total revenue [3] - The company launched multiple innovative products domestically, including the Cratos branched aortic stent system and other medical devices [3] - The product sales network now covers 49 countries and regions, including China [3] Product Development and Pipeline - The company has a robust pipeline with several products in various stages of development, including the Aegis II abdominal aortic stent system and the Hector thoracic multi-branch stent system [4] - The company is actively pursuing international registrations for its innovative products, including CE and FDA approvals [4] - New peripheral intervention products are expected to be approved for market launch in 2026 [4]